Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CBP 1018

Next Previous
Drug Profile

CBP 1018

Alternative Names: CBP-1018; MVB-101

Latest Information Update: 23 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Coherent Biopharma (Suzhou)
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Peptide drug conjugates
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 16 Jun 2026 Multivalent Biotherapies plans a phase Ib/IIa trial for Prostate cancer in the US (IV) in third quarter of 2026
  • 22 Dec 2025 CBP 1018 licensed to Multivalent Biotherapies worldwide
  • 13 Feb 2025 Updated efficacy and adverse events data from a phase I/II trial in Prostate cancer presented at the 2025 Genitourinary Cancers Symposium (ASCO-GeCS-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top